- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07584122
Improving Access to PrEP (HIV Prevention Medication) for People in Underserved Areas of Rio de Janeiro
Bringing PrEP to Underserved Communities in Rio de Janeiro: the PrEPOUT Rio Study
This study aims to improve access to HIV prevention using pre-exposure prophylaxis (PrEP) among underserved populations in Rio de Janeiro, including gay and bisexual men, transgender women, and sex workers. Despite the proven effectiveness of PrEP, many people at higher risk of HIV face barriers to accessing and continuing this prevention method, especially those living in socially and economically vulnerable communities.
The study will evaluate whether offering PrEP directly in community-based settings-such as non-governmental organizations, mobile health units, and through telehealth and digital tools-can increase its uptake and continued use. Participants who test negative for HIV will be offered daily oral PrEP, along with counseling and follow-up support. Those who test positive will be referred for appropriate treatment.
The main hypothesis is that delivering PrEP in community settings, combined with supportive strategies like mobile health interventions, will be feasible, acceptable, and more effective in reaching and engaging vulnerable populations, ultimately helping to reduce new HIV infections.
연구 개요
상태
정황
상세 설명
The PrEPOUT Rio Study is designed to evaluate the implementation of community-based strategies to expand access to and engagement with oral pre-exposure prophylaxis (PrEP) for HIV prevention among underserved populations in Rio de Janeiro and the metropolitan area, including Nova Iguaçu. The study focuses on populations disproportionately affected by HIV, such as gay, bisexual, and other men who have sex with men (MSM), transgender women, other sexual and gender minorities, and sex workers.
The study will be conducted in three phases. The formative phase will use qualitative methods, including focus group discussions with key stakeholders and members of the target population, to identify barriers and facilitators to PrEP uptake and to inform the adaptation of community-based delivery strategies.
In the implementation phase, PrEP will be offered in non-traditional settings, including community-based organizations and mobile health units, aiming to reduce structural and social barriers to access. Trained healthcare staff will provide on-site HIV testing, counseling, and PrEP initiation. Participants who test HIV-negative will be offered daily oral PrEP, while those diagnosed with HIV will be promptly referred for treatment within the public health system. The study will also incorporate supportive strategies such as telehealth consultations and mobile health (mHealth) interventions to enhance adherence, retention, and engagement in care.
The evaluation phase will include both quantitative and qualitative approaches to assess implementation and clinical outcomes. Quantitative data will be collected through structured questionnaires and clinical assessments to evaluate PrEP uptake, adherence, persistence, and HIV incidence, as well as the acceptability and feasibility of the intervention. Qualitative data from follow-up focus groups will provide insights into participants' experiences and perceptions of community-based PrEP delivery models.
The primary objective is to assess the feasibility and acceptability of delivering PrEP in community-based settings. Secondary objectives include evaluating engagement with telehealth and digital tools, identifying barriers and facilitators to PrEP use, and assessing HIV and sexually transmitted infection (STI) outcomes in the study population. The findings are expected to inform scalable strategies to improve equitable access to HIV prevention services in settings with significant social and structural inequalities.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Beatriz Grinsztejn
- 전화번호: +55 2138659128
- 이메일: beatriz.grinsztejn@gmail.com
연구 장소
-
-
Rio de Janeiro
-
Nova Iguaçu, Rio de Janeiro, 브라질, 26030-380
- 모병
- Hospital Geral de Nova Iguaçu
-
연락하다:
- José Henrique Pilotto, PhD
- 이메일: pilotto@uninet.com.br
-
Rio de Janeiro, Rio de Janeiro, 브라질, 21040360
- 모병
- Instituto Nacional de Infectologia Evandro Chagas
-
연락하다:
- Emilia Jalil, PhD
- 전화번호: 55 2138659128
- 이메일: emiliajalil@gmail.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Individuals aged 15 years or older
- Gay, bisexual, and other men who have sex with men (MSM)
- Transgender women and travestis
- Other sexual and gender minorities (SGM)
- Cisgender women in situations of social or economic vulnerability
- Sex workers
- Individuals seeking HIV testing and/or pre-exposure prophylaxis (PrEP)
- HIV-negative at screening
- Willing and interested in initiating PrEP
- Eligible for PrEP according to Brazilian national guidelines
Exclusion Criteria:
- Positive HIV test result at screening or during study participation
- Individuals not eligible for PrEP according to Brazilian national guidelines
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 건강 서비스 연구
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Community-Based PrEP Delivery
Participants will receive HIV prevention services through a community-based delivery model, including HIV testing, counseling, and initiation of daily oral pre-exposure prophylaxis (PrEP) according to national guidelines.
Services will be provided in non-traditional settings, such as non-governmental organizations and mobile health units, with additional support through telehealth and mobile health (mHealth) strategies to enhance engagement, adherence, and retention in care.
Participants diagnosed with HIV during screening or follow-up will be referred for treatment within the public health system.
|
Participants will receive daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), in accordance with Brazilian national guidelines for HIV prevention.
PrEP will be offered to eligible individuals who test HIV-negative at enrollment and during follow-up, with clinical monitoring and counseling provided as part of routine care.
Participants will receive HIV prevention services through community-based delivery strategies designed to reduce barriers to access.
These include provision of services in non-traditional settings such as non-governmental organizations and mobile health units, with on-site HIV testing, counseling, and same-day PrEP initiation by trained healthcare staff.
Participants will have access to telehealth consultations and mobile health (mHealth) interventions to support engagement in care, adherence to PrEP, and retention in follow-up.
These strategies may include remote clinical support, digital communication tools, and tailored adherence support interventions.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Feasibility of Community-Based PrEP Delivery
기간: Up to 12 months
|
Feasibility will be assessed by the proportion of planned community-based PrEP service delivery activities successfully implemented.
Indicators will include: (1) number of community-based sites activated, (2) number of individuals screened for HIV, and (3) number of participants initiating PrEP.
Results will be summarized using counts and proportions.
|
Up to 12 months
|
|
Acceptability of Community-Based PrEP Delivery
기간: Up to 12 months
|
Acceptability will be assessed using participant-reported outcomes collected through a structured acceptability questionnaire with Likert-scale items.
Scores will range from 1 to 5, with higher scores indicating greater acceptability of the intervention.
|
Up to 12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
PrEP Uptake
기간: Up to 12 months
|
Proportion of eligible participants who initiate PrEP after HIV testing and counseling in community-based settings.
|
Up to 12 months
|
|
PrEP Persistence (Retention in PrEP Care)
기간: Up to 12 months
|
Proportion of participants who remain engaged in PrEP care over time, including continued use of PrEP and attendance at follow-up visits.
|
Up to 12 months
|
|
HIV Incidence
기간: Up to 12 months
|
Number of new HIV infections diagnosed among study participants during the follow-up period.
|
Up to 12 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 혈액 매개 감염
- 비뇨생식기 질환
- 생식기 질환
- 면역계 질환
- 감염
- RNA 바이러스 감염
- 바이러스 질환
- 전염병
- 성병, 바이러스성
- 성병
- 렌티바이러스 감염
- 레트로바이러스과 감염
- 면역 결핍 증후군
- HIV 감염
- 보건 서비스 관리
- 건강 관리 제공
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 핵산, 뉴클레오티드 및 뉴 클레오 시드
- 공중 위생
- 환경 및 공중 보건
- 퓨린
- 데 옥시 시티 딘
- 시티 딘
- 피리 미딘 뉴 클레오 시드
- 피리 미딘
- 건강 서비스
- 의료 시설 인력 및 서비스
- 예방 보건 서비스
- 유기 인 화합물
- 뉴 클레오 시드
- 데 옥시 리보 뉴 클레오 시드
- 유기 포스 포네이트
- 아데닌
- 공중 보건 관행
- 환자 치료 관리
- 1 차 예방
- 테노포비어
- 엠트리시타빈
- 원격 의료
- 사전 노출 예방
기타 연구 ID 번호
- 84111624.4.1001.5262
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .